|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 903.3 DKK | -1.05% |
|
-0.73% | +29.39% |
| 10:54am | Roche: share price stands out, Deutsche Bank in support | CF |
| 05-16 | Health Care Flat as Momentum Wanes -- Health Care Roundup | DJ |
(MT Newswires) -- Novo Nordisk (NVO) sales surged in the third quarter and double-digit growth should carry into 2024, driven by burgeoning demand for its obesity and diabetes blockbuster drugs Ozempic and Wegovy. Novo Nordisk Chief Financial Officer Karsten Munk Knudsen speaks on "Bloomberg Brief."
| 1st Jan change | Capi. | |
|---|---|---|
| +29.39% | 593B | |
| +32.32% | 694B | |
| -1.56% | 371B | |
| +20.06% | 331B | |
| +7.18% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.82% | 169B | |
| -0.60% | 164B |
NOVO NORDISK A/S 
